Monoclonal Antibodies


Merck to acquire Prometheus Biosciences for $10.8bn

By Rachel Arthur

Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.


BioNTech and OncoC4 team up on novel checkpoint antibody

By Rachel Arthur

BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....


Monoclonal antibody offers new way to protect against malaria

By Rachel Arthur

One dose of an antibody drug protected from malaria infection during the malaria season in Mali, showing up to 88% effectiveness: demonstrating for the first time that a monoclonal antibody can prevent malaria in an endemic region.


WHO recommends two mAbs in fight against Ebola

By Rachel Arthur

The World Health Organization (WHO) has published its first guidelines for Ebola virus disease therapeutics, issuing ‘strong recommendations’ for the use of two monoclonal antibodies.


Chinook Therapeutics creates JV for kidney disease therapies in China

By Rachel Arthur

Chinook Therapeutics, Inc. has announced the formation of SanReno Therapeutics - a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China - to develop, manufacture and commercialize kidney disease...